PE20060286A1 - Derivados de piperidina o piperazina como antagonistas del receptor cgrp - Google Patents

Derivados de piperidina o piperazina como antagonistas del receptor cgrp

Info

Publication number
PE20060286A1
PE20060286A1 PE2005000346A PE2005000346A PE20060286A1 PE 20060286 A1 PE20060286 A1 PE 20060286A1 PE 2005000346 A PE2005000346 A PE 2005000346A PE 2005000346 A PE2005000346 A PE 2005000346A PE 20060286 A1 PE20060286 A1 PE 20060286A1
Authority
PE
Peru
Prior art keywords
piperidin
piperidine
indazol
oxo
antagonists
Prior art date
Application number
PE2005000346A
Other languages
English (en)
Inventor
Andrew P Degnan
Xiaojun Han
Gene M Dubowchik
Stephen E Mercer
John E Macor
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20060286A1 publication Critical patent/PE20060286A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I DONDE V ES -N(R1)(R2) O OR4; R4 ES H, ALQUILO C1-C6, HALOALQUILO C1-C4, ENTRE OTROS; R1 Y R2 SON L1, DONDE L1 ES H, ALQUILO C1-C6, FENILO, ENTRE OTROS; Q ES Q' O Q''; Q' ES ALQUILENO C1-C3-R3, ENTRE OTROS; Q'' ES NH(ALQUILO C1-C3)R3, ENTRE OTROS; R3 ES R3a O R3b; R3a ES FENILO, HIDROXIFENILO, NAFTILO, ENTRE OTROS; R3b ES DIHIDROBENZIMIDAZOLONILO, BENZTIAZOLILO, 1H-INDAZOL-5-IL, ENTRE OTROS; D ES O, NCN O NSO2ALQUILO C1-C3; A ES C, N, CH O COH; m Y n SON 0, 1 O 2; p ES 1, G, J Y E FORMAN AX O AY; AX ES UN HETEROCICLO FUSIONADO QUE TIENE DOS ANILLOS FUSIONADOS CON 5 A 7 MIEMBROS EN CADA UNO DE LOS ANILLOS, EL HETEROCICLO CONTIENE DE 1 A 4 HETEROATOMOS SELECCIONADOS DE O, N Y S; AY ES UN HETEROCICLO DE 4 A 6 MIEMBROS QUE TIENE DE 1 A 3 HETEROATOMOS SELECCIONADOS DE O, N Y S. SON COMPUESTOS PREFERIDOS: 3-(7-METIL-1H-INDAZOL-5-IL)-1-OXO-1-(4-PIPERIDIN-1-IL)PIPERIDIN-1-IL)PROPAN-2-IL 4-(1,2-DIHIDRO-2-OXOQUINAZOLIN-3(4H)-IL)PIPERIDINA-1-CARBOXILATO, (R)-3-(7-METIL-1H-INDAZOL-5-IL)-1-OXO-1-(4-PIPERIDIN-1-IL)PIPERIDIN-1-IL)PROPAN-2-IL 4-(2-OXO-1,2-DIHIDROQUINAZOLIN-3(4H)-IL)PIPERIDINA-1-CARBOXILATO, ENTRE OTROS. TAMBIEN REFERIDA A METODOS DE PREPARACION Y COMPOSICIONES QUE CONTIENEN DICHOS COMPUESTOS, LOS CUALES SON ANTAGONISTAS DE LOS RECEPTORES PEPTIDOS RELACIONADOS CON EL GEN DE CALCITONINA Y SON UTILES EN EL TRATAMIENTO DE LA VASODILATACION NEUROGENICA, MIGRANA, ENTRE OTROS
PE2005000346A 2004-03-29 2005-03-28 Derivados de piperidina o piperazina como antagonistas del receptor cgrp PE20060286A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55740804P 2004-03-29 2004-03-29

Publications (1)

Publication Number Publication Date
PE20060286A1 true PE20060286A1 (es) 2006-04-25

Family

ID=34964257

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000346A PE20060286A1 (es) 2004-03-29 2005-03-28 Derivados de piperidina o piperazina como antagonistas del receptor cgrp

Country Status (16)

Country Link
US (1) US7772244B2 (es)
EP (1) EP1730137A1 (es)
JP (1) JP2007530701A (es)
KR (1) KR20070007857A (es)
CN (1) CN1972929A (es)
AR (1) AR048343A1 (es)
AU (1) AU2005228881A1 (es)
BR (1) BRPI0509341A (es)
CA (1) CA2562039A1 (es)
IL (1) IL178291A0 (es)
NO (1) NO20064888L (es)
PE (1) PE20060286A1 (es)
RU (1) RU2006138195A (es)
TW (1) TW200533398A (es)
WO (1) WO2005095383A1 (es)
ZA (1) ZA200608037B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
CA2487976C (en) * 2002-06-05 2011-07-26 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
RU2007109794A (ru) * 2004-08-19 2008-09-27 Вертекс Фармасьютикалз, Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
AU2005309365B2 (en) * 2004-11-29 2011-10-06 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7449586B2 (en) * 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CN101146799A (zh) 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 Cgrp拮抗剂、其制备方法以及其作为药物的用途
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
DE102005050892A1 (de) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
AU2006330866A1 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1988892A2 (en) 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ATE517106T1 (de) * 2006-02-22 2011-08-15 Vertex Pharma Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
CN101500565A (zh) * 2006-06-29 2009-08-05 弗特克斯药品有限公司 毒蕈碱性受体的调节剂
CN101553231A (zh) * 2006-08-15 2009-10-07 弗特克斯药品有限公司 毒蕈碱受体调节剂
JP2010501561A (ja) 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
JP2010508358A (ja) * 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
CA2700724A1 (en) * 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
FR3008978A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
JO3669B1 (ar) 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
UY38050A (es) 2018-01-12 2019-07-31 Amgen Inc Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0851759A4 (en) 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
WO1998009630A1 (en) 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
ES2314305T3 (es) * 1996-09-10 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su obtencion.
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO1999052875A1 (en) 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
EP1117662A1 (en) 1998-09-30 2001-07-25 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19963868A1 (de) 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2002010140A2 (en) 2000-08-01 2002-02-07 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Imidazolyl derivatives
US6982263B2 (en) * 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
EP1438325B1 (en) 2001-09-27 2009-12-30 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
DE10206770A1 (de) 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US6900317B2 (en) * 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
CA2487976C (en) 2002-06-05 2011-07-26 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP4673294B2 (ja) 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
CA2518830A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Carboxamide spirohydantoin cgrp receptor antagonists
CA2518852A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Monocyclic anilide spirohydantoin cgrp receptor antagonists
CA2519515A1 (en) 2003-03-14 2004-10-14 Merck & Co., Inc. Benodiazepine spirohydantoin cgrp receptor antagonists
ATE516803T1 (de) 2003-03-14 2011-08-15 Merck Sharp & Dohme Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
US20040248816A1 (en) * 2003-04-01 2004-12-09 Boehringer Ingelheim International Gmbh Treatment of migraine
JP4705908B2 (ja) 2003-04-15 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体拮抗薬
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CA2529227A1 (en) 2003-06-26 2005-01-06 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
CA2529196A1 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
US20050032783A1 (en) * 2003-07-07 2005-02-10 Boehringer Ingelheim International Gmbh Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
EP1689493A4 (en) 2003-12-05 2008-04-23 Bristol Myers Squibb Co ANTAGONISTS OF THE CALCITONIN GENE RELATED PEPTIDE RECEPTOR
AU2005208834B2 (en) 2004-01-29 2009-10-08 Merck Sharp & Dohme Corp. CGRP receptor antagonists
EP1722792A1 (de) * 2004-03-03 2006-11-22 Boehringer Ingelheim International GmbH Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018796A1 (de) 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) * 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018795A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
CA2563687A1 (en) 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
US7696195B2 (en) * 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004027912A1 (de) * 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) * 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US8662081B2 (en) 2005-02-15 2014-03-04 Yale University Intrauterine device

Also Published As

Publication number Publication date
JP2007530701A (ja) 2007-11-01
AR048343A1 (es) 2006-04-19
EP1730137A1 (en) 2006-12-13
WO2005095383A1 (en) 2005-10-13
US7772244B2 (en) 2010-08-10
US20050215576A1 (en) 2005-09-29
CA2562039A1 (en) 2005-10-13
RU2006138195A (ru) 2008-05-10
NO20064888L (no) 2006-10-26
KR20070007857A (ko) 2007-01-16
IL178291A0 (en) 2006-12-31
CN1972929A (zh) 2007-05-30
ZA200608037B (en) 2008-06-25
BRPI0509341A (pt) 2007-09-04
AU2005228881A1 (en) 2005-10-13
TW200533398A (en) 2005-10-16

Similar Documents

Publication Publication Date Title
PE20060286A1 (es) Derivados de piperidina o piperazina como antagonistas del receptor cgrp
PE20060076A1 (es) Antagonistas del receptor de acetilcolina muscarinico
PE20060620A1 (es) Analogos de biaril piperazinil-piridina sustituidos como moduladores del receptor de capsaicina vr1
PE20050429A1 (es) Derivados de 2-fenilamino-4-amino-pirimidina como inhibidores de quinasa, composicion farmaceutica que los contiene y proceso de preparacion
PE20091884A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparacion, asi como su uso como medicamento
AR042691A1 (es) Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas.
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
AR076098A1 (es) Derivados de benzofurano
AR055878A1 (es) Derivados de ciclopropanocarboxamida
PE20051036A1 (es) Antagonistas del receptor peptido relacionado con el gen de calcitonina
AR076860A1 (es) Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
PE20110371A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20090733A1 (es) Derivados de pirazina como bloqueadores de los canales de sodio epitelial
CO5200757A1 (es) Derivados de 4-indol benzamidas con actividad contra la osteoporosis, sus sales farmaceuticamente aceptables y composiciones farmaceuticas que los contienen
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR038235A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
AR057104A1 (es) Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica
AR058769A1 (es) Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.
AR062156A1 (es) Compuestos agonistas y selectivos del receptor s1p-1
RU2009120882A (ru) Соединения и композиции, как ингибиторы протеинкиназы
PE20010628A1 (es) Compuestos de amina ciclica, su produccion y su uso
AR058554A1 (es) Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
AR057848A1 (es) Diarilureas para el tratamiento de la hipertension pulmonar
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol

Legal Events

Date Code Title Description
FC Refusal